All In Biotech

Drug Trial Radar · NCT03594110

EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

A Multicentre International Randomized Parallel Group Double-blind Placebo-controlled Clinical Trial of EMPAgliflozin Once Daily to Assess Cardio-renal Outcomes in Patients With Chronic KIDNEY Disease

Last checked: Nov 19, 2026Latest source record: Jul 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 6,609 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,609

Actual

Start

Jan 31, 2019

Primary completion

Jul 5, 2022

Study completion Jul 2, 2024

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
Collaborators
University of Oxford; Eli Lilly and Company
First posted
Jul 20, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary aim of the study is to investigate the effect of empagliflozin on kidney disease progression or cardiovascular death versus placebo on top of standard of care in patients with pre-existing chronic kidney disease. After completion of the interventional part of the study (primary study completion) a subset of participants will be followed up in a post-trial observational (non-interventional) manner for cardio-renal outcomes (estimated study completion date).

Conditions

  • Chronic Kidney Disease

Interventions

  • EmpagliflozinDrug

    Taken daily with or without food

  • Matching placeboDrug

    Taken daily with or without food

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Interventional Part: Time to First Occurrence of Kidney Disease Progression or Cardiovascular Death ('as Adjudicated')Time frame: From the day of randomisation to the day of the final follow-up visit in the interventional part of the trial, up to 1136 days.
  2. Overall Study: Time to the First Occurrence of Kidney Disease Progression or Cardiovascular Death ('as Adjudicated')Time frame: From the day of randomization in the interventional part of the trial until the individual day of end of study in the non-interventional part of the trial. Up to 1869 days.

Locations

240 sites in 8 countries. Site status is shown where the registry gives one.

  • Nephrology Consultants, LLC

    Huntsville, Alabama

  • Aventiv Research, Inc

    Mesa, Arizona

  • Southern California Permanente Medical Group

    San Diego, California

  • University of California Los Angeles

    Sylmar, California

  • University of California Los Angeles

    Torrance, California

  • Yale University School of Medicine

    New Haven, Connecticut

  • Chase Medical Research, LLC

    Thomaston, Connecticut

  • Midland Florida Clinical Reearch Center, LLC

    DeLand, Florida

  • University of Florida

    Gainesville, Florida

  • East Coast Institute for Research, LLC

    Jacksonville, Florida

  • East Coast Clinical Research, Inc

    Lake City, Florida

  • Total Research Group, LLC

    Miami, Florida

  • Hanson Clinical Research Center, Inc.

    Port Charlotte, Florida

  • Emory University

    Atlanta, Georgia

  • The Jones Center for Diabetes and Endocrine Wellness

    Macon, Georgia

  • Cedar Crosse Research Center

    Chicago, Illinois

  • Northwestern University

    Chicago, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Saint Elizabeth Healthcare

    Covington, Kentucky

  • Lexington VA Health Care System - Troy Bowling Campus

    Lexington, Kentucky

  • Medstar Health Research Institute

    Baltimore, Maryland

  • Kidney Care and Transplant Services of New England, PC

    West Springfield, Massachusetts

  • Saint Clair Specialty Physicians

    Roseville, Michigan

  • Clinical Research Consultants, LLC

    Kansas City, Missouri

  • VA Southern Nevada Healthcare System

    North Las Vegas, Nevada

  • Seacoast Kidney and Hypertension Specialists

    Portsmouth, New Hampshire

  • SUNY Downstate Medical Center

    Brooklyn, New York

  • Mountain Kidney and Hypertension Associates, PA

    Asheville, North Carolina

  • The University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Brookview Hills Research Associates LLC

    Winston-Salem, North Carolina

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina

  • University Hospitals of Cleveland

    Cleveland, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Carolina Diabetes & Kidney Center

    Sumter, South Carolina

  • Regional Health Clinical Research

    Rapid City, South Dakota

  • Research Institute of Dallas

    Dallas, Texas

  • Renal Disease Research Institute

    Dallas, Texas

  • Academy Of Diabetes, Thyroid And Endocrine, PA

    El Paso, Texas

  • Pioneer Research Solutions, Inc.

    Houston, Texas

Showing 40 of 240 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.